TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01898793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-803
Study: NCT01069458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The high protein diet group and the low fat diet group
Description: The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
Study: NCT01898793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood for correlative studies
Description: -Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood for correlative studies
Description: -Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse
Study: NCT01069458

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The high protein diet group and the low fat diet group
Description: The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
Study: NCT01638260

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NEAT
Description: Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
Study: NCT01827553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with gemcitabine or FOLFIRINOX
Description: According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m\^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m\^2 2 h infusion, folinic acid 400 mg/ m\^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m\^2 for 90 minutes, bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherapy with gemcitabine or FOLFIRINOX
Description: According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m\^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m\^2 2 h infusion, folinic acid 400 mg/ m\^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m\^2 for 90 minutes, bolus application 5-FU 400 mg/m\^2 followed by 46h infusion of 5-FU 2400 mg/m\^2)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy, 28 x 1.8 Gy
Description: Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
Study: NCT01898793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood for correlative studies
Description: -Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood for correlative studies
Description: -Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood for correlative studies
Description: -Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood for correlative studies
Description: -Screening, Day 0 prior to CIML NK infusion, Day 1, Day 3, Day 7, Day 8, Day 10, Day 14, Day 21, Day 28, Day 42, Day 60, Day 100, 6 months, 9 months, 12 months, and at disease relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow for correlative studies
Description: -Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
Study: NCT01002209

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham HBO
Description: HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.~For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included.
Study: NCT01898793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow for correlative studies
Description: -Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow for correlative studies
Description: -Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow for correlative studies
Description: -Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow for correlative studies
Description: -Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow for correlative studies
Description: -Screening, Day 8, Day 14, Day 28, Between Day 42 and 60, Day 100, at disease relapse
Study: NCT03787316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study group
Description: 4 weeks of custom-made insoles in the home and outside the home environment , follow the home exercise program during this process.It is planned to perform gait parameters and pain assessment before and after the treatment.
Study: NCT05281250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise
Description: A supervised exercise is randomized. Although this intervention is not standard in our setting, it is a recommended practice, since it is known that rehabilitation strategies in hospitalized patients have different benefits.
Study: NCT01813565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid/chondroitin sulfate
Description: Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
Study: NCT01827553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy, gemcitabine
Description: 5 cycles of 300 mg/m\^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m\^2/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy
Description: Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m\^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
Study: NCT04749173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003, 96mg
Description: Drug: Placebo Intramuscularly injection at predefined injection sites
Study: NCT01813565

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid/chondroitin sulfate
Description: Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
Study: NCT05731934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HX301
Description: At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
Study: NCT03330535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders once a week
Description: Participants in this group will receive active oral hygiene reminders through text messaging once a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Verbal oral hygiene instructions
Description: Participants in this group will receive verbal oral hygiene instructions during their regular orthodontic visits every 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders three times a week
Description: Participants in this group will receive active oral hygiene reminders through text messaging three times a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily reminders
Description: Participants in this group will receive active oral hygiene reminders through text messaging on a daily basis.
Study: NCT02610868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MYOBLOC
Description: After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
Study: NCT03940209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic needs navigation
Description: Navigators will help participants address unmet basic needs for 6 months by telephone. Either party can initiate a call. On every call, navigators will: (1) review unmet needs previously reported (baseline survey for first call) and ask participants to report new needs; (2) jointly prioritize among multiple needs based on severity and resource availability; (3) identify community resources that could help solve the problem; (4) evaluate eligibility for those resources; and (5) prepare participants to interact with service agencies and/or act as an advocate on their behalf. On each subsequent call, navigators will review progress toward resolving those needs, assess emergent needs, and adapt priorities accordingly. Navigators will provide instrumental and emotional social support through regular friendly contact, and will attempt to reduce barriers to needs resolution to improve stability and security for participants longer-term.
Study: NCT01651572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Description: Cisatracurium (Nimbex):~* initial dose: 0.2 mg/kg~* maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium (Esmeron):~* initial dose: 0.6 mg/kg~* maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)
Study: NCT03146650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04047290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: AK112 is a PD1/VEGF bispecific antibody.
Study: NCT00682019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5mg, 10mg or 20mg taken 8 hours before sexual intercourse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT03215212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye mask
Description: eye mask administered from 10 pm to 7 am

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye mask
Description: eye mask administered from 10 pm to 7 am

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye mask
Description: eye mask administered from 10 pm to 7 am

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocean sound
Description: Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocean sound
Description: Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ocean sound
Description: Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm